Literature DB >> 30147629

Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Manish K Jha1, Madhukar H Trivedi1.   

Abstract

Entities:  

Year:  2018        PMID： 30147629      PMCID： PMC6103647          DOI： 10.1176/appi.focus.20180013

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN： 1541-4094


× No keyword cloud information.
  56 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY.

Authors:  Tracy L Greer; Joseph M Trombello; Chad D Rethorst; Thomas J Carmody; Manish K Jha; Allen Liao; Bruce D Grannemann; Heather O Chambliss; Timothy S Church; Madhukar H Trivedi
Journal:  Depress Anxiety       Date:  2016-05-10       Impact factor: 6.505

3.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

Review 4.  The role of inflammation in depression: from evolutionary imperative to modern treatment target.

Authors:  Andrew H Miller; Charles L Raison
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

Review 5.  A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.

Authors:  David A Mrazek; John C Hornberger; C Anthony Altar; Irina Degtiar
Journal:  Psychiatr Serv       Date:  2014-08-01       Impact factor: 3.084

6.  Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.

Authors:  Madhukar H Trivedi; A John Rush; Bradley N Gaynes; Jonathan W Stewart; Stephen R Wisniewski; Diane Warden; Louise Ritz; James F Luther; Diane Stegman; Joanne Deveaugh-Geiss; Robert Howland
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

7.  Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression.

Authors:  Jonathan E Alpert; David Mischoulon; Grace E F Rubenstein; Kathryn Bottonari; Andrew A Nierenberg; Maurizio Fava
Journal:  Ann Clin Psychiatry       Date:  2002-03       Impact factor: 1.567

8.  Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.

Authors:  Christopher E M Griffiths; Maurizio Fava; Andrew H Miller; James Russell; Susan G Ball; Wen Xu; Nayan Acharya; Mark Hyman Rapaport
Journal:  Psychother Psychosom       Date:  2017-09-14       Impact factor: 17.659

9.  Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans.

Authors:  J A Clements; W S Nimmo; I S Grant
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

10.  Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Arun V Ravindran; Sidney H Kennedy; M Claire O'Donovan; Angelo Fallu; Fernando Camacho; Carin E Binder
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.